Modern Treatment Approaches for Central Serous Retinopathy (CSR)

The management of Central Serous Retinopathy (CSR), also known as Central Serous Chorioretinopathy (CSCR), has evolved significantly with advances in retinal imaging and a better understanding of the role of the choroid–retinal pigment epithelium (RPE) complex.

Treatment decisions are now individualised, based on factors such as the duration of fluid, recurrence, visual symptoms, retinal damage risk, OCT findings and the patient's visual requirements.

1. Observation and Lifestyle Modification

Many acute CSR episodes resolve spontaneously, particularly within the first 3–4 months.

Initial management may include:

• Careful observation with serial Optical Coherence Tomography (OCT) monitoring

• Reviewing and avoiding unnecessary corticosteroid exposure where possible (in discussion with the prescribing doctor)

• Addressing contributing factors such as stress, hypertension and sleep disorders

• Managing associated conditions such as obstructive sleep apnoea

Regular follow-up is important because persistent or recurrent CSR can lead to permanent changes in the retina and reduced visual function.

2. Photodynamic Therapy (PDT) — The Established Treatment for Chronic CSR

Photodynamic Therapy (PDT) has become one of the most effective evidence-based treatments for chronic or recurrent CSR.

PDT uses an intravenous photosensitising drug (verteporfin) activated by a low-energy laser to target abnormal choroidal vascular activity.

Modern approaches include:

• Half-dose PDT

• Half-fluence PDT

• Reduced-duration PDT

These modified protocols aim to reduce treatment-related risks while maintaining effectiveness.

Benefits include:

• Reduction of subretinal fluid

• Improvement in choroidal hyperpermeability

• Lower recurrence rates in many patients

• Preservation of retinal function

PDT is particularly useful in patients with persistent CSR, recurrent disease or evidence of pachychoroid changes.

3. Mineralocorticoid Pathway Modulation

The association between CSR and cortisol-related pathways led to interest in mineralocorticoid receptor antagonists such as:

• Eplerenone

• Spironolactone

Although early studies showed promise, larger clinical trials have not demonstrated consistent benefit, and these treatments are not considered standard therapy for CSR.

Research continues into the role of hormonal pathways in CSR.

4. Focal Laser Treatment

Laser treatment may be considered in selected cases where leakage points are clearly identified away from the central fovea.

Potential benefits:

• Closure of focal leakage areas

• Faster resolution of fluid

Limitations:

• Not suitable for leakage close to the centre of vision

• Limited role in diffuse CSR or pachychoroid-related disease

• Risk of retinal scarring if not carefully selected

5. Anti-VEGF Injections

Anti-VEGF injections (commonly used for wet AMD) are not routinely effective for typical CSR, as CSR is not primarily driven by VEGF-related leakage.

However, anti-VEGF treatment may be appropriate if CSR is complicated by:

• Secondary choroidal neovascularisation (CNV)

• Pachychoroid neovasculopathy

• Polypoidal choroidal vasculopathy

Accurate diagnosis with OCT and angiographic imaging is essential before considering injections.

6. Emerging and Investigational Treatments

Research continues into new approaches targeting the underlying mechanisms of CSR, including:

• Choroidal vascular regulation

• Inflammatory pathways

• Oxidative stress

• Complement system modulation

• RPE protection and repair

These may provide future treatment options for patients with chronic or difficult-to-treat CSR.

Personalised CSR Management by a Medical Retina Specialist

Modern CSR treatment is no longer based on a "one treatment fits all" approach. A detailed assessment with advanced retinal imaging helps determine:

• Whether observation is appropriate

• Whether treatment is needed

• Which treatment offers the best balance of benefit and safety

• The risk of recurrence or long-term retinal damage

With over 18 years of experience in Medical Retina, Mr Kumar provides specialist assessment and management of Central Serous Retinopathy for patients from Reading, Windsor, Berkshire and surrounding areas, using evidence-based treatment strategies tailored to each patient's retinal findings and visual needs.